Coag Drugs Flashcards Preview

IHO > Coag Drugs > Flashcards

Flashcards in Coag Drugs Deck (22):
1

Asprin

Irreversibly inhibits COX, preventing thromboxane A2 formation and platelet aggregation. AE: bleeding, tinnitus at high doses.

2

Clopidogrel

(plavix) irreversible ADP receptor antagonist, preventing platelet activation and fibrin formation. Used before stenting, AE: nausea, diarrhea, bleeding rash. Severe lukopenia(r). Requires CYP2C19 , drug drug.

3

Ticopidine

irreversible ADP receptor antagonist, preventing platelet activation and fibrin formation. Used before stenting, AE: nausea, diarrhea, bleeding rash. Severe lukopenia(r). Thrombotic, thrmbocytopenic purpura Most side effects

4

Prasugrel

irreversible ADP receptor antagonist, preventing platelet activation and fibrin formation. Used before stenting, AE: nausea, diarrhea, bleeding rash. Severe lukopenia(r).

5

Dipyridamole

Increases cAMP and inhibits platelet activation. Inhibits platelt uptake of adenosine, thus increases adenosine interaction with Adenosine A2 receptor leading to icreased cAMP. Also vasodilator AE: headaches. given with asprin or warfarin.

6

Abciximab

Humanized Mab against GPIIb/IIIa receptor, inhibitor, prevents binding of adhesive glycoproteins such as fibrinogen and vWF to activated platelets. Given IV w/ aspirin and heparin for acute coronary syndromes. AE: bleeding and thrombocytopenia

7

Eptifibatide

fibrinogen analogue against GPIIb/IIIa receptor, inhibitor, prevents binding of adhesive glycoproteins such as fibrinogen and vWF to activated platelets. Given IV w/ aspirin and heparin for acute coronary syndromes. AE: bleeding and thrombocytopenia

8

Tirofiban

fibrinogen analogue nonpeptide competitive inhibitor against GPIIb/IIIa receptor, inhibitor, prevents binding of adhesive glycoproteins such as fibrinogen and vWF to activated platelets. Given IV w/ aspirin and heparin for acute coronary syndromes. AE: bleeding and thrombocytopenia

9

Unfractionated heparin

Indirect thrombin inhibitor, also accelerates inactivation of factor Xa. (same as high molecular weight heparin. Prevents clotting, no monitoring, AE: bleeding, heparin inducedthrombocytopenia, lowest bioavailability, highest antidote effect.

10

Low molecular Weight heparin

Indirect thrombin inhibitor, also accelerates inactivation of factor Xa. Prevents clotting, no monitoring, AE: bleeding, heparin induced thrombocytopenia, lowered antidote effect

11

Fondaprinux

Synthetic heparin. accelerates inactivation of factor Xa. Prevents clotting, no monitoring, AE: bleeding, low heparin induced thrombocytopenia risk. best bioavailability, No antidote effect

12

Leirudin

Direct thrombin inhibitor, Binds directly to thrombin and inhibits the enzyme. Derivative of leech hirudin

13

Bivalirudin

Direct thrombin inhibitor, Binds directly to thrombin and inhibits the enzyme.

14

Argatroban

Direct thrombin inhibitor, Binds directly to thrombin and inhibits the enzyme.

15

Dabigatran etexilate

(oral) Binds directly to thrombin and inhibits the enzyme.

16

Protamine

Is the antidote for heparins, binds and forms a stable complex with heparin which lacks anticoagulant activity. has less effect on low MW heparin, and no effect on fondaparinux.

17

Warfarin

Blocks synthesis of vitamin K dependant clotting factors II , VII, IX, X, and PROTEIN C/S by inhibiting vitamin K reductase. Vitamin K antidote, and must bridge with heparin because Protein C/S have very short half lives and increased clotting results. Interacts with P450 enzymes.

18

Phytonadione

Vitamin K. is antidote for warfarin. Used in clotting factors, II, VII, IX,X and proteins C/S.

19

Urokinase

Kidney Enzyme that directly converts plasminogen to plasmin

20

Alteplase

Fibrinolytic drug. Preferentially activate plasminogen that is bound to fibrin which confines it to the thrombus rather than systemic activation. Dissolves existing life threatening thrombi, activates plasminogen, IV, narrow spectrum. Used for stroke.

21

Reteplase

Fibrinolytic drug. Preferentially activate plasminogen that is bound to fibrin which confines it to the thrombus rather than systemic activation. Dissolves existing life threatening thrombi, activates plasminogen, IV, narrow spectrum. Used for stroke.

22

Tenecteplase

Fibrinolytic drug. Preferentially activate plasminogen that is bound to fibrin which confines it to the thrombus rather than systemic activation. Dissolves existing life threatening thrombi, activates plasminogen, IV, narrow spectrum. Used for stroke.